Quick Order

BLyS / TNFSF13B / BAFF Antibody, Rabbit PAb

    DatasheetReviewsRelated ProductsProtocols
    Human TNFSF13B Antibody Product Information
    Immunogen:Recombinant Human BAFF / TNFSF13B protein (Catalog#10056-HNAE)
    Clone ID:
    Ig Type:Rabbit IgG
    Concentration:
    Endotoxin:
    Formulation:0.2 μm filtered solution in PBS
    Preparation:Produced in rabbits immunized with purified, recombinant Human BAFF / TNFSF13B (rh BAFF / TNFSF13B; Catalog#10056-HNAE; Q9Y275-1; Ala134-Leu285). Total IgG was purified by Protein A affinity chromatography.
    Other TNFSF13B Antibody Products
    BAFF/BLyS/TNFSF13B Background

    B lymphocyte stimulator (BLyS), also known as TNFSF13B, CD257 and BAFF, is single-pass type II membrane protein, which belongs to the tumor necrosis factor family. BAFF is abundantly expressed in peripheral blood Leukocytes and is specifically expressed in monocytes and macrophages. BAFF is a cytokine and serves as a ligand for receptors TNFRSF13B (TACI), TNFRSF17 (BCMA), and TNFRSF13C (BAFFR). These receptors is a prominent factor in B cell differentiation, homeostasis, and selection. BLyS levels affect survival signals and selective apoptosis of autoantibody-producing B cells. Thus, it acts as a potent B cell activator and has been shown to play an important role in the proliferation and differentiation of B cells. Overexpression of BLyS in mice can lead to clinical and serological features of systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS). BLyS as an attractive therapeutic target in human rheumatic diseases. The ability of BLyS to regulate both the size and repertoire of the peripheral B cell compartment raises the possibility that BLyS and antagonists thereof may form the basis of a therapeutic trichotomy. As an agonist, BLyS protein may enhance humoral immunity in congenital or acquired immunodeficiencies such as those resulting from viral infection or cancer therapy.

    Immune Checkpoint   Immunotherapy   Cancer Immunotherapy   Targeted Therapy

    Human BAFF/BLyS/TNFSF13B References
  • Nardelli B, et al. (2002) B lymphocyte stimulator (BLyS): a therapeutic trichotomy for the treatment of B lymphocyte diseases. Leuk Lymphoma. 43(7): 1367-73.
  • Stohl W. (2006) Therapeutic targeting of B lymphocyte stimulator (BLyS) in the rheumatic diseases. Endocr Metab Immune Disord Drug Targets. 6(4): 51-8.
  • Cancro MP, et al. (2009) The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest. 119(5): 1066-73.
  • Product nameProduct name
    Size / Price
    Catalog: 10056-RP01-100
    List Price: 
    Price:      (You Save: )

    Datasheet & Documentation

    All information of our products is subject to change without notice. Please refer to COA enclosed in shipped package for the newest information.
    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"